Telix制药启动全球三期临床试验，用于新型胶质母细胞瘤治疗。 Telix Pharmaceuticals starts global Phase 3 trial for new glioblastoma treatment.

Telix制药公司在全球第三期试验中为第一位患者注射了质母细胞瘤复发的新疗法. Telix Pharmaceuticals has dosed the first patient in a global Phase 3 trial for a new treatment of recurrent glioblastoma. 这项研究测试了与化疗相结合的放射性药物和单独使用化学治疗, 针对脑瘤细胞中过度表达的转运体. The study tests a radiopharmaceutical combined with chemotherapy versus chemotherapy alone, targeting a transporter overexpressed in brain tumor cells. 早期结果显示出有希望的生存率,该疗法已获得孤儿药物指标,尽管它仍在研究中. Early results have shown promising survival rates, and the therapy has received orphan drug designation, though it remains investigational.